SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 29, 2020 for Deepak Kumar Inani SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 29, 2020 for Omprakash Inani
Shilpa Medicare share price locked at lower circuit on 15 observations from USFDA
The company is preparing responses to the observations, which will be submitted to the Agency within 15 business days. Shilpa Medicare Ltd - 530549 - Sub: Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg. Ref: Stock Code: NSE: SHILPAMED/BSE-530549
We hereby inform that the US FDA conducted Good Manufacturing Practices (GMP) inspection of Shilpa Medicare Ltd's Finished Dosage Formulation Facility (Sterile and Non-sterile) located at S-20 to S-26, Pharmaceutical Formulations SEZ, TSIIC, Jadcherla, Telangana State, India from 13-25, Feb 2020. At the conclusion of inspection, the Agency issued Form 483, with 15 observations. The company is preparing responses to the observations, which will be submitted to the Agency within 15 business days. The company is committed to address these observations promptly. With Regards
Shilpa Medicare locked in upper circuit after board nod for biological unit sale
The sale of biological unit is subject to the approval of shareholders and is expected to be completed on or before March 31. Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Meeting Updates
This is to intimate that the Board of Directors of the Company at its meeting held today, approved the sale of Biological Unit of Shilpa Medicare Limited by way of Slump Sale to Shilpa Biologicals Private Limited, a Wholly Owned Subsidiary of the Company subject to the approval of Shareholders. The detailed disclosure as required under Regulation 30 of SEBI (LODR) Regulations, 2015 is attached hereto as Annexure - A. The Board also authorised the Managing Director and other officials of the Company to finalize and issue a notice to the members seeking their approval for the above said proposal and also to do all the needful thereto. Kindly take the record of the same. Shilpa Medicare hits fresh 52-week high; stock zooms 89% in a month
The company's Ebitda margin expanded by 1,550 basis points to 32.1 per cent in Q3FY20 from 16.6 per cent in Q3FY19 Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Investor Presentation
Sub: Presentation made to Analysts and Investors Ref: Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015; Scrip Code: BSE - 530549/ Stock Symbol: NSE - SHILPAMED Pursuant to the Securities and Exchange Board of India( Listing Obligations and Disclsoure Requirements) Regulations, 2015, as amended from time to time, please find herewith enclosed a copy of the presentation on the financial performance for the 3rd Quarter and 9 Months ended 31st December, 2019 made to analysts and investors. This is for your information and necessary records. Shilpa Medicare Ltd - 530549 - RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2019
With reference to the captioned subject, Please be noted that pursuant to the Resolution passed at the meeting of the board of directors held on 10th November, 2020 at 11:30 A.M. the following items have taken on record. 1. The unaudited Financial Results (Standalone and Consolidated) for the quarter ended 31st December, 2019, pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015. The Statement of Financial Results along with Statement of Assets and Liabilities, Cash Flow Statements and Limited review reports are enclosed as Annexure-1. It is further intimated that meeting commenced at 02:30 P.M. and concluded at 06:15 PM This is for your information and necessary records SHILPA MEDICARE LTD. - 530549 - Ref: Regulation 30 Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015; Scrip Code: BSE - 530549/ Stock Symbol: NSE - SHILPAMED
With reference to the captioned subject, Please be noted that pursuant to the Resolution passed at the meeting of the board of directors held on 10th November, 2020 at 11:30 A.M. the following items have taken on record. 1. The unaudited Financial Results (Standalone and Consolidated) for the quarter ended 31st December, 2019, pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015. The Statement of Financial Results along with Statement of Assets and Liabilities, Cash Flow Statements and Limited review reports are enclosed as Annexure-1. It is further intimated that meeting commenced at 11:30 A.M. and concluded at This is for your information and necessary records.